Investors

Arcus Ventures (AV) consists of a team of professionals with experience in clinical and academic medicine, drug development, hospital management, healthcare industry consulting and private equity. AV is dedicated to investing in oncology focused companies with innovative biopharmaceuticals and or new drug delivery platforms in development, device companies with products that have pre-marketing approval, and service companies with positive revenue.

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on investing in life science companies that advance human health. Domain’s focused network, deep experience, and dependable reputation of this team have made it one of the top private-equity groups participating in healthcare investing. With more than $2.7 billion in capital raised, Domain invests in three major segments: pharmaceuticals, diagnostics, and medical devices. The partners of Domain have a total of more than 270 person-years of experience among them in the healthcare and venture capital industries and have been involved in the formation and growth of more than 250 life sciences companies. Representative past investments include Amgen, Amylin Pharmaceuticals, Cerexa, Biosite, Dura Pharmaceuticals, Pharmion and Volcano. Domain has offices in Princeton, N.J. and San Diego.

Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, and Innovation division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry.

The Roche Venture Fund invests in innovative biotech and diagnostics companies to develop commercially successful life science companies.  Based in Basel with an office in South San Francisco, RVF is the corporate venture fund of the healthcare company Roche.  RVF invests globally with a portfolio of over 30 companies in 10 countries.

Founded in 2012, RusnanoMedInvest is a venture capital firm created to effect the partnership between the Russian RUSNANO State Corporation and Domain Associates, L.L.C. signed in March 2012. RMI is headquartered in Moscow, Russia. Life sciences Venture Fund RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100-percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. RMI’s key objectives are to advance projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.